




AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. 2918/3A/US (PC31017)	
Applicant(s): Susan A. Gregory					
Application No. 10/617,222	Filing Date 7/10/2003	Examiner Brian Young S. Kwon	Customer No. 26,648	Group Art Unit 1614	Confirmation No. 2378
Invention: IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR INHIBITOR					
 COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	4 -	13 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	2 -	3 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1025 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
 Signature			Dated: September 2, 2005		
Philip B. Polster, II, Reg. No. 43,864			I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on September 2, 2005 (Date)  Signature of Person Mailing Correspondence Christine Noonan Typed or Printed Name of Person Mailing Correspondence		
CC:					

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Susan A. Gregory) GROUP ART UNIT: 1614
)
SERIAL NO.: 10/617,222) CONFIRMATION NO.: 2378
)
EXAMINER: Brian Young S. Kwon) ATTORNEY DOCKET
) NO.: 2918/3A/US
FILED: July 10, 2003) (PC31017)

TITLE: IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A
CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4
RECEPTOR INHIBITOR

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 2, 2005 .

Christine Noonan
Christine I. Noonan

2918/3A/US

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

Sir:

This letter is in response to the Office Action dated June 2, 2005, with a three-month shortened statutory period which is set to expire on September 2, 2005. The Applicants believe that this response is timely filed, however, please charge any appropriate fees to Deposit Account No 19-1025.

Amendments begin on page 3 of this paper.

Remarks begin on page 13 of this paper.